Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers
US10775385B2 · kind B2 · utility
7Cited by
7References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 22, 2015 |
| Grant date | Sep 15, 2020 |
| Priority date | — |
| Expiry date | Oct 22, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/04
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.